Hidenori Kitai

Jul 18, 2024 | nature.com | Hidenori Kitai |Yu Yang |Rui Yamaguchi |Hiromichi Ebi |David Wildes |Mallika Singh | +1 more

AbstractCurrent KRASG12C (OFF) inhibitors that target inactive GDP-bound KRASG12C cause responses in less than half of patients and these responses are not durable. A class of RASG12C (ON) inhibitors that targets active GTP-bound KRASG12C blocks ERK signaling more potently than the inactive-state inhibitors. Sensitivity to either class of agents is strongly correlated with inhibition of mTORC1 activity.